Patents Assigned to Kagoshima University
-
Publication number: 20240148807Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.Type: ApplicationFiled: January 5, 2024Publication date: May 9, 2024Applicant: Kagoshima UniversityInventors: Ken-ichiro KOSAI, Nobuhiro Ijichi
-
Patent number: 11965035Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: April 23, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
-
Publication number: 20240124577Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.Type: ApplicationFiled: August 1, 2023Publication date: April 18, 2024Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO
-
Patent number: 11896635Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.Type: GrantFiled: November 8, 2018Date of Patent: February 13, 2024Assignee: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro Kosai, Nobuhiro Ijichi
-
Patent number: 11873337Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: January 16, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
-
Publication number: 20230414718Abstract: An agent for protecting and/or regenerating pancreatic ? cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.Type: ApplicationFiled: November 18, 2021Publication date: December 28, 2023Applicant: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro KOSAI, Eriko MATSUDA
-
Patent number: 11701440Abstract: Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.Type: GrantFiled: April 15, 2019Date of Patent: July 18, 2023Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL UNIVERSITY CORPORATION KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Shota Komoto, Yu Ogawa, Yoshinari Shoyama, Tadashi Hatano, Yuji Ito, Yasushi Arano, Hiroyuki Suzuki, Tomoya Uehara
-
Publication number: 20230181587Abstract: This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: May 7, 2021Publication date: June 15, 2023Applicants: KAGOSHIMA UNIVERSITY, OSAKA UNIVERSITYInventors: Takashi KURIHARA, Ichiro TAKASAKI, Hitoshi HASHIMOTO, Atsuko HAYATA, Yusuke SHINTANI
-
Patent number: 11643474Abstract: An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.Type: GrantFiled: August 1, 2019Date of Patent: May 9, 2023Assignees: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji Ito, Seiichi Uchimura, Hiromichi Okura
-
Patent number: 11583463Abstract: A hemiplegic forearm function recovery training device includes a forearm mounting part (2) on which a forearm (S) is to be mounted. The forearm mounting part (2) includes a mounting body (20), an inner frame portion (2B), an outer frame portion (2A), and a control part. The mounting body (20) has a forearm fixing portion (22) on which the forearm (S) is mounted and a gripping mechanism (23) capable of being gripped by a hand of the forearm (S). The inner frame portion (2B) is fitted to the mounting body (20) and is rotatable around the forearm (S). The outer frame portion (2A) guides the inner frame portion (2B) in a rotation direction thereof. The control part performs a series of controls that repeatedly causes normal rotation, stop, reverse rotation, and stop of the inner frame portion (2B) while acquiring rotation angle information of the inner frame portion (2B).Type: GrantFiled: August 31, 2018Date of Patent: February 21, 2023Assignees: Kagoshima University, Marumae Co., Ltd.Inventors: Yong Yu, Takashi Morimoto, Toshikazu Maeda, Koei Igarashi
-
Patent number: 11571416Abstract: Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections.Type: GrantFiled: April 13, 2018Date of Patent: February 7, 2023Assignee: Kagoshima UniversityInventors: Robert A. Davey, Yasuteru Sakurai, Masanori Baba, Norikazu Sakakibara
-
Patent number: 11491219Abstract: The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.Type: GrantFiled: October 4, 2018Date of Patent: November 8, 2022Assignees: TOKYO YAKUHIN KOGYO CO., LTD., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases, KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITYInventors: Taizou Kamishita, Takashi Miyazaki, Michinori Kohara, Takahiro Sanada, Yoichi Hiasa, Osamu Yoshida, Kyoko Kohara, Hideki Hasegawa
-
Patent number: 11472865Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.Type: GrantFiled: May 18, 2018Date of Patent: October 18, 2022Assignee: Kagoshima UniversityInventor: Yuji Ito
-
Patent number: 11473530Abstract: A readily combustible portion (110) includes a readily combustible exposed surface (111) that is exposed to a flow channel (CA). A combustion-resistant portion (140), which comprises a material that is more resistant to combustion than the readily combustible portion (110), covers an outer surface of the readily combustible portion (110) on the opposite side from the readily combustible exposed surface (111) in a direction orthogonal to a length direction parallel to a direction in which a hybrid rocket is propelled. The combustion-resistant portion (140) includes a thick portion (120) that serves as a stopper that prevents peeling of the readily combustible portion (110) from the combustion-resistant portion (140) in a direction from a starting end surface (100a) toward a terminating end surface (100b).Type: GrantFiled: June 27, 2019Date of Patent: October 18, 2022Assignee: KAGOSHIMA UNIVERSITYInventor: Hiroshi Katanoda
-
Patent number: 11432742Abstract: A nasal-cavity model generator (41) extracts pixels having pixel density values within a specific range from three-dimensional image data on a nasal cavity of a subject contained in DICOM data (21), and generates a nasal cavity model (50), which is a three-dimensional model of the nasal cavity, based on three-dimensional image data composed of the extracted pixels. A nasal-cavity resistance calculator (42) calculates a nasal cavity resistance (51) through fluid analysis using the nasal cavity model (50) generated by the nasal-cavity model generator (41). An adjuster (43) adjusts the specific range of the pixel density values of the pixels to be extracted for generation of the nasal cavity model (50) by the nasal-cavity model generator (41) such that the nasal cavity resistance (51) calculated by the nasal-cavity resistance calculator (42) is equal to a nasal cavity resistance (52) actually measured with a nasal-cavity draft gauge.Type: GrantFiled: March 1, 2018Date of Patent: September 6, 2022Assignee: KAGOSHIMA UNIVERSITYInventors: Tomonori Iwasaki, Youichi Yamasaki
-
Patent number: 11365194Abstract: This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: GrantFiled: September 27, 2018Date of Patent: June 21, 2022Assignees: KAGOSHIMA UNIVERSITY, SHOWA UNIVERSITYInventors: Takashi Kurihara, Ichiro Takasaki, Naoki Toyooka, Hiroaki Gouda
-
Publication number: 20220184081Abstract: This invention relates to an antipruritic agent of formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: February 12, 2020Publication date: June 16, 2022Applicant: KAGOSHIMA UNIVERSITYInventors: Takashi KURIHARA, lchiro TAKASAKl, Naoki TOYOOKA, Hiroaki GOUDA
-
Publication number: 20220152187Abstract: The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, KAGOSHIMA UNIVERSITY, NAGASAKI UNIVERSITYInventors: Michinori KOHARA, Fumihiko YASUI, Daisuke YAMANE, Kyoko KOHARA, Kouichi MORITA, Yasuhiro YASUTOMI, Koji ISHII
-
Publication number: 20220033432Abstract: The present disclosure aims to provide an anti-hepatitis B virus agent, and a prophylactic or therapeutic agent for a hepatitis B virus-related disease, each comprising a nucleic acid analogue as an active ingredient. The above object can be attained by an anti-hepatitis B virus agent, or a prophylactic or therapeutic agent for a hepatitis B virus-related disease, each comprising, as an active ingredient, a compound represented by the following formula (1): wherein R is a halogen atom, an amino group, a methoxy group, or a cyano group, or its prodrug, or a pharmaceutically acceptable salt thereof, or a solvate thereof.Type: ApplicationFiled: September 13, 2021Publication date: February 3, 2022Applicants: DAIKIN INDUSTRIES, LTD., KAGOSHIMA UNIVERSITYInventors: Tomohito HAMADA, Hideyuki IKEUCHI, Kanako INOO, Yosuke KISHIKAWA, Masanori IKEDA, Midori TAKEDA
-
Publication number: 20220025044Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.Type: ApplicationFiled: August 11, 2021Publication date: January 27, 2022Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITYInventors: Nobuaki TAKAHASHI, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO